Journal:
:iranian journal of pharmaceutical research
0
mina golestani school of pharmacy, shahid beheshti university of medical sciences, tehran, iran, iranian center of excellence in health management, faculty of management and medical informatics, tabriz university of medical sciences, tabriz, iran
peyman eshghi pediatric hematology and oncology , pediatric congenital hematologic disorders research center, shahid beheshti university of medical sciences, tehran, iran
hamid reza rasekh school of pharmacy, shahid beheshti university of medical sciences, tehran, iran
abdoll majid cheraghali school of pharmacy, university of baqiyatallah medical sciences, tehran, iran
jamshid salamzadeh school of pharmacy, shahid beheshti university of medical sciences, tehran,iran
majid naderi genetics of non-communicable disease research center, zahedan university of medical sciences, zahedan, iran
abstract nowadays, bypassing agents such as recombinant activated factor vii (rfviia) and activated prothrombin complex concentrates (apcc) are used to treat bleeding episodes in the hemophilia patients with inhibitors. aryoseven® is an iranian biogeneric rfviia with homogeneity of efficacy and the nature to novoseven in a comparative trial. the current clinical trial aimed to evaluate the cost...